At present, some individual doctors are exaggerating the efficacy of long-acting interferon in treating hepatitis B virus and claiming that its efficacy in clearing hepatitis B virus can reach more than 90%, and some patients are so eager to seek medical treatment that they insist on treatment even if they have to sell their pots and pans or houses. I hope that the majority of patients will read the following information before making a decision. The following is information on the efficacy of long-acting interferon: International multicenter randomized controlled clinical trials have shown that HBeAg-positive chronic hepatitis B patients treated with pegylated interferon a-2a (PegIFN-a2a) (87% of Asians) for 48 weeks had a HBeAg serological conversion rate of 32% at 24 weeks of discontinuation follow-up; the HBeAg serological conversion rate was up to 43% at 48 weeks of discontinuation follow-up. The conversion rate of HBeAg serology was up to 43% at 48 weeks. Overseas studies have shown that similar rates of HBVDNA suppression, HBeAg seroconversion, and HBsAg disappearance can be achieved with pegylated interferon a-2b (PegIFN-a2b) in HBeAg-positive chronic hepatitis B. In HBeAg-negative chronic hepatitis B patients (60% Asian) treated with PegIFN-a2a for 48 weeks, the rate of HBV DNA <2*104 copies/mL (equivalent to 2000 IU/mL) was 43% at 24 weeks post-discontinuation and 42% at 48 weeks post-discontinuation; the rate of HBsAg disappearance was 3% at 24 weeks post-discontinuation and increased to 8% at 3 years post-discontinuation. The rate of HBsAg disappearance was 3% at 24 weeks of discontinuation and increased to 8% at 3 years of discontinuation. Predictors of antiviral efficacy of interferon: better efficacy is often achieved with (1) high pre-treatment ALT levels; (2) HBV DNA < 2*108 copies/ml; (3) female; (4) short duration of disease; (5) non-maternal-to-child transmission; (6) heavy inflammatory necrosis and mild fibrosis of liver tissue; (7) good compliance with treatment; (8) no HCV, HDV or HIV co-infection; (9) HBV genotype A; and (10) undetectable serum HBVDNA at 12 or 24 weeks of treatment. Among them, pre-treatment ALT, HBV DNA level and HBV genotype, are important factors to predict the efficacy.